论文部分内容阅读
目的研究血管生成素(Angs)与多发性骨髓瘤(MM)的关系并探讨其临床意义。方法用双抗体夹心酶联免疫吸附测定法检测60例MM患者不同时期的Angs血清浓度,观察其与MM临床分期、肿瘤量分级和治疗效果的关系。结果 MM患者血清中Ang-2较正常对照组明显升高;血清Ang-1含量与正常对照组差异无统计学意义。MM患者Ⅱ期的Ang-2血清水平显著低于Ⅲ期。不同肿瘤量分级的MM患者血清Ang-2含量差异有统计学意义。MM治疗有效者,血清Ang-2水平比治疗前明显降低,血清Ang-1水平与治疗前差异无统计学意义;治疗无效者,其血清Ang-1、Ang-2含量与治疗前比较差异均无统计学意义。结论 MM患者血清Ang-2水平测定对MM的发病机制研究、病情评价、疗效监测、预后预测有一定意义。
Objective To study the relationship between angiopoietin (Angs) and multiple myeloma (MM) and to explore its clinical significance. Methods The serum levels of Angs in 60 MM patients at different stages were detected by double antibody sandwich enzyme-linked immunosorbent assay (ELISA), and their relationship with clinical stage, tumor grade and therapeutic effect were observed. Results The serum level of Ang-2 in MM patients was significantly higher than that in normal control group. There was no significant difference between the two groups in serum Ang-1 level and normal control group. The level of Ang-2 in stage II patients with MM was significantly lower than that in stage III. The serum Ang-2 levels in MM patients with different tumor grade were significantly different. The levels of serum Ang-2 in serum of patients with MM were significantly lower than those before treatment, and the serum levels of Ang-1 were not significantly different from those before treatment. The patients with ineffective treatment had lower serum Ang-1 and Ang-2 levels than those before treatment No statistical significance. Conclusion The serum level of Ang-2 in patients with MM has certain significance for the pathogenesis of MM, disease evaluation, efficacy monitoring and prognosis prediction.